In this segment of the IMWG Conference Series, “Making Sense of Treatment,” leading myeloma experts discuss the latest drug therapy news from the annual American Society of Hematology (ASH) conference. Moderated by IMF Chairman of the Board Dr. Brian G.M. Durie, panelists include Thomas Martin, MD (University of California at San Francisco), María V. Mateos, MD, PhD (University of Salamanca – Salamanca, Spain), and IMF Nurse Leadership Board Member Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN (Cleveland Clinic, Taussig Cancer Institute – Cleveland). The panel will focus on the 879 abstracts that were multiple-myeloma-related from the ASH 2021 conference.
These abstracts cover the following topics:
- A new look at early disease: MGUS & SMM
- Minimal residual disease (MRD) monitoring
- Frontline therapy with four drug combinations
- Immune therapies, including CAR T-cell therapies and bispecifics
- Emerging new treatments
